Saturday July 20, 2019

Addyi: an antidepressant, not female Viagra

0
//

25FactsAboutFlibanserin  By NewsGram Staff Writer

While sexual problems remain a more clandestine affair for women than men, a respite in the name of Addyi has been introduced. This pink pill can pull out women from their depression which is caused due to their sexual inactivity.

With the US FDA giving a green signal to Flibanserin, commonly known as Addyi, the pharmaceutical industry has received its first drug which can treat a flagging or absent libido in women.

Addyi is erroneously being called as the “female Viagra”. However, that is not the case! While Viagra treats erectile dysfunction and focuses on the genitals of a man, Addyi works on the central nervous system, thereby targeting the brain and not the genitals.

Sprout Pharmaceuticals, the manufacturer of this pill won the FDA approval after two consecutive rejections in the year 2010 and 2013 respectively. The approval of Addyi is accompanied by various side-effects and caveat. Since Addyi targets the brain, it is classified under the category of antidepressants.

This drug comes with side-effects that include dizziness, nausea, fatigue and somnolence. While Viagra is a pill that men take before a sexual encounter, Addyi needs to be taken everyday. Moreover, this pill can be prescribed only by doctors and apothecaries who watch an online presentation and pass a test related to it.

lady-viagra

This prescription of this drug doesn’t entail that the woman is ill or is undergoing some relationship problems. Instead, this pill is dispensed for women whose loss of sexual desire causes marked distressed or depression in some cases.

While Dr Lauren Streicher, associate professor of clinical obstetrics and gynecology at Northwest University believes that this pill will induce women to talk about their sexual problems, Adriane Fugh-Berman, a pharmacology professor and director of PharmedOut thinks that such drugs open way for other “bad drugs” to enter into the market.

Next Story

FDA Warns Patients about Cybersecurity Concerns with Certain Medtronic Insulin Pumps

Patients with diabetes using the affected models should switch their insulin pump to models that are better equipped

0
ransomware
The ransomware takes advantage of the architecture of the central processing unit (CPU) to avoid detection - functionality that is not often seen in ransomware. Pixabay

With the US Food and Drug Administration (FDA) issuing a warning to health care providers this week that certain Medtronic insulin pumps have potential cybersecurity risks, the company said no patient issues have been reported in India so far.

While the US FDA said that Medtronic was recalling several affected MiniMed pumps and providing alternative insulin pumps to patients, insulin pumps are not being recalled in India.

Patients with diabetes using the affected models should switch their insulin pump to models that are better equipped to protect against these potential risks, the FDA said.

Medtronic India said it has started notifying customers of a potential cybersecurity risk in the MiniMed 508 and MiniMed Paradigm series of insulin pumps. These models are from 2012 and earlier.

US, FDA, Cybersecurity
With the US Food and Drug Administration (FDA) issuing a warning to health care providers this week that certain Medtronic insulin pumps have potential cybersecurity risks. Pixabay

“An unauthorised person with special technical skills and equipment could potentially connect wirelessly to a nearby insulin pump to change settings and control insulin delivery. At this time, we have not received any confirmed reports of unauthorized persons changing settings or controlling insulin delivery,” Medtronic India said in a statement.

“Kindly note that the insulin pumps are not being recalled and are not required to be returned. This is a safety notification only,” it added.

MiniMed 508 had been discontinued in India since 2011.

Also Read- Central Government to Launch ‘One Nation, One Ration Card’ Scheme in a Bid to Curb Corruption

“In India, Medtronic is proactively informing the regulators and other relevant stakeholders and is in the process of working with researchers, doctors and patients to address any questions or concerns that they may have,” the US-based medical device manufacturer said. (IANS)